Apceth, a leader in the development of stem cell treatments, has won approval for a Phase I/II multicenter clinical trial evaluating an autologous mesenchymal stem cell (MSC) therapy for gastrointestinal cancer. The treatment involves the utilization of the patient’s own stem cells to combat and destroy cancerous cells and is designed to enable highly localized treatments.
Apceth’s novel use of stem cells to treat cancer is indicative of the impact stem cell based treatments will have on medicine. Using the patient’s own [autologous] stem cells to treat a broad range of disease, trauma and injury represents the emerging gold standard in regenerative medicine.
Banking your own stem cells when they are young, vital, and proliferative is the best way to assure access to these emerging regenerative therapies. To learn how to bank your own valuable stem cells, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The future of Regenerative Medicine is now™